OliX PharmaceuticalsInc (226950.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea · ISIN KR7226950004

Price
91,400.00 KRW
Market cap
1.86 tn KRW
P/E (2025)
–
P/S (2025)
126.51
Dividend yield
0.00 %
Net margin
-107.33 %
Return on equity (ROE)
-10.54 %
Return on assets (ROA)
-8.06 %

OliX PharmaceuticalsInc financials

Fiscal year20242025
Revenue5.68 bn KRW14.67 bn KRW
Gross profit5.68 bn KRW14.67 bn KRW
Operating income-38.61 bn KRW-29.97 bn KRW
EBIT-36.41 bn KRW-11.43 bn KRW
Net income-40.66 bn KRW-15.74 bn KRW
Diluted EPS – continuing operations-2,202.58 KRW-775.48 KRW

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About OliX PharmaceuticalsInc

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.